ABBVIE
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT05268068
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital /ID# 212830, Shanghai, Shanghai, China
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 263
- Registration Number
- NCT05264129
- Locations
- 🇺🇸
Advanced Research Institute - Ridgeline /ID# 242662, Ogden, Utah, United States
🇺🇸Clinvest Research LLC /ID# 242597, Springfield, Missouri, United States
🇺🇸Aventiv Research Columbus /ID# 242462, Columbus, Ohio, United States
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 986
- Registration Number
- NCT05248893
- Locations
- 🇺🇸
Perelman Center for Advanced Medicine - /ID# 243966, Philadelphia, Pennsylvania, United States
🇺🇸Northwest Dermatology Institute /ID# 233498, Portland, Oregon, United States
🇺🇸Swinyer-Woseth Dermatology /ID# 241250, Salt Lake City, Utah, United States
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 638
- Registration Number
- NCT05248867
- Locations
- 🇺🇸
Clinical Testing of Beverly Hills /ID# 233195, Encino, California, United States
🇺🇸Westside Aesthetics /ID# 232443, Los Angeles, California, United States
🇺🇸Steven Fagien MD Aesthetic Eyelid Plastic Surgery /ID# 232439, Boca Raton, Florida, United States
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- AbbVie
- Registration Number
- NCT05217472
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht /ID# 214029, Utrecht, Netherlands
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 75
- Registration Number
- NCT05216263
- Locations
- 🇺🇸
Michigan Headache & Neurological Institute (MHNI) /ID# 241784, Ann Arbor, Michigan, United States
🇺🇸Minneapolis Clinic of Neurology - Burnsville /ID# 241994, Burnsville, Minnesota, United States
🇺🇸Albany Medical College /ID# 242757, Albany, New York, United States
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
- Conditions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 125
- Registration Number
- NCT05215639
- Locations
- 🇦🇹
Klinikum Klagenfurt am Wörthersee /ID# 247304, Klagenfurt am Wörthersee, Kaernten, Austria
🇨🇭Duplicate_Universitätsspital Basel /ID# 256509, Basel, Basel-Stadt, Switzerland
🇨🇭Inselspital, Universitaetsspital Bern /ID# 239241, Bern, Switzerland
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 174
- Registration Number
- NCT05216250
- Locations
- 🇺🇸
Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 231731, Phoenix, Arizona, United States
🇺🇸Accel Research Sites - Neurology and Neurodiagnostics of Alabama, LLC /ID# 240472, Hoover, Alabama, United States
🇺🇸University of Arizona /ID# 239781, Tucson, Arizona, United States
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 115
- Registration Number
- NCT05210803
- Locations
- 🇺🇸
California Retina Consultants, Santa Barbara, California, United States
🇺🇸Northern California Retina Vitreous Associates Medical Group Inc, Mountain View, California, United States
🇺🇸Southeast Retina Center PC, Augusta, Georgia, United States
An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 97
- Registration Number
- NCT05170646
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust /ID# 251706, Cambridge, United Kingdom
🇬🇧The Royal Wolverhampton NHS Trust /ID# 251708, Wolverhampton, United Kingdom
🇬🇧Medway NHS Foundation Trust /ID# 244673, Gillingham, Kent, United Kingdom